ERBB2 and mastitis: From a system-level standpoint, especially in regions with limited access to advanced imaging, implementing standardized protocols that mandate early biopsy for non-resolving mastitis in young women could significantly improve diagnostic timelines and reduce treatment delays.The identification of HER2-positive IDC with inflammatory features underscores the need for a high index of suspicion for malignancy when breast inflammation persists or worsens, even if imaging initially suggests a benign process.